The illustrated PD-1 mechanism of action and the role it plays in the pathogenesis of a variety of cancers coupled with its unique structure—resembling that of cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) but with a unique ligand specificity and biological functionality—makes it an exceptional drug target (48). The gene discussed is PDCD1; the disease is cancer.